High court seems likely to side with Merck in Fosamax case
WASHINGTON (AP) — The Supreme Court seems likely to side with drugmaker Merck in a dispute over the warning label on its bone-strengthening drug Fosamax.
During arguments Monday in a lawsuit against the New Jersey-based company, only two justices seemed inclined to rule against Merck. A trial court initially threw out claims against Merck. An appeals court revived them.
The case before the Supreme Court involves hundreds of people who sued Merck, alleging they were injured by Fosamax. They say they suffered Fosamax-related thigh-bone fractures and that Merck failed to provide adequate warnings on the drug’s label.
Merck says the Food and Drug Administration rejected its warning attempt because the FDA believed available data didn’t initially support one.
Fosamax is prescribed to prevent and treat osteoporosis in women who have gone through menopause.
The Western Journal has not reviewed this Associated Press story prior to publication. Therefore, it may contain editorial bias or may in some other way not meet our normal editorial standards. It is provided to our readers as a service from The Western Journal.
Truth and Accuracy
We are committed to truth and accuracy in all of our journalism. Read our editorial standards.
Advertise with The Western Journal and reach millions of highly engaged readers, while supporting our work. Advertise Today.
